Show Search Form

Search Results

human indexable	true false
published	true false
registered interest	true false
answer date	exactly: or between: and
date	exactly: or between: and
date tabled	exactly: or between: and
ddp created	exactly: or between: and
answering body
question status
answering dept id
answering dept short name
answering dept sort name
ddp modified
hansard heading
house id
identifier
legislature
parliament number
question first answered
question text
session
session number
tabling member constituency
tabling member printed
title
type
uin
version
written parliamentary question type
answer	answer text answering member constituency
creator	label written parliamentary question
publisher
tabling member

Search

1127083

	human indexable
	published
	registered interest
	answer date	20/05/2019
	date	16/05/2019
	date tabled	16/05/2019
	ddp created	16/05/2019 16:39:25
	answering body	Department for Transport
	question status	Tabled
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	ddp modified	16/05/2019 16:45:38 23/05/2019 11:07:02
	hansard heading	Motorways: Safety
	house id	1
	identifier	255306
	legislature	25259
	parliament number	57
	question first answered	23/05/2019 10:35:52
	question text	To ask the Secretary of State for Transport, how many additional emergency refuge areas he plans to add to existing stretches of all lane running motorways in the next twelve months.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 255306
	type	WrittenParliamentaryQuestion
	uin	255306
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In the next twelve months construction work will commence to install 10 additional emergency refuge areas on the M25.</p><p> </p><p>In addition, Highways England are also enhancing the visibility of emergency areas on all new and existing smart motorways by installing orange surfacing and improved, more frequent signs. These changes are designed to help drivers feel more confident that they can find a safe place to stop in an emergency.</p><p> </p> answering member constituency Hereford and South Herefordshire
	creator	1528 label Biography information for Sir Mike Penning written parliamentary question 1128441
	publisher	25259
	tabling member	1528

1127084

	human indexable
	published
	registered interest
	answer date	20/05/2019
	date	16/05/2019
	date tabled	16/05/2019
	ddp created	16/05/2019 16:39:28
	answering body	Department for Transport
	question status	Tabled
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	ddp modified	16/05/2019 16:45:40 23/05/2019 11:16:01
	hansard heading	Motorways: Safety
	house id	1
	identifier	255307
	legislature	25259
	parliament number	57
	question first answered	23/05/2019 10:44:22
	question text	To ask the Secretary of State for Transport, what his Department's timescale is for all lane running motorways to have emergency refuge areas spaced at no more than one mile apart.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 255307
	type	WrittenParliamentaryQuestion
	uin	255307
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>To help drivers feel more confident they can find a place to stop in an emergency, Highways England have committed to reducing the maximum spacing of emergency areas which is currently about every mile and a half (about 90 seconds at 60mph), to around every mile (about every minute at 60mph). This will take place on schemes being constructed from 2020 onwards.</p><p> </p> answering member constituency Hereford and South Herefordshire
	creator	1528
	publisher	25259
	tabling member	1528

1127085

	human indexable
	published
	registered interest
	answer date	20/05/2019
	date	16/05/2019
	date tabled	16/05/2019
	ddp created	16/05/2019 16:39:31
	answering body	Department for Transport
	question status	Tabled
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	ddp modified	16/05/2019 16:45:45 23/05/2019 11:10:17
	hansard heading	Traffic Officers: Injuries
	house id	1
	identifier	255308
	legislature	25259
	parliament number	57
	question first answered	23/05/2019 10:38:41
	question text	To ask the Secretary of State for Transport, what data his Department collects on the number of Highways England traffic officers who are injured while on duty each year.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 255308
	type	WrittenParliamentaryQuestion
	uin	255308
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In accordance with the Reporting of Injuries, Diseases and Dangerous Occurrences Regulations (RIDDORS) 2013 and as part of its Health and management system, Highways England collects data for all its staff, including Traffic Officers in the following categories:- RIDDOR Fatality, RIDDOR Specified Injury, RIDDOR Greater than 7 day absence from work, lost time injury between 4 and 7 day, lost time injury between 1 and 3 days.</p><p> </p> answering member constituency Hereford and South Herefordshire
	creator	1528
	publisher	25259
	tabling member	1528

1127086

	human indexable
	published
	registered interest
	answer date	20/05/2019
	date	16/05/2019
	date tabled	16/05/2019
	ddp created	16/05/2019 16:39:35
	answering body	Department for Transport
	question status	Tabled
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	ddp modified	16/05/2019 16:45:48 23/05/2019 11:18:02
	hansard heading	Motorways: Safety
	house id	1
	identifier	255309
	legislature	25259
	parliament number	57
	question first answered	23/05/2019 10:47:00
	question text	To ask the Secretary of State for Transport, what comparative assessment his Department has made of the relative safety of breaking down in a live lane on an all lane running motorway and a motorway that has a hard shoulder.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 255309
	type	WrittenParliamentaryQuestion
	uin	255309
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>The original safety assessment of all lane running included the safety of a vehicle stopping in a running lane during peak and off-peak periods. It also identified a range of measures, such as the provision of traffic management technology and emergency areas, designed to ensure overall all lane running safety levels would be at least as safe as those of a traditional motorway with a hard shoulder.</p><p> </p><p>The smart motorway schemes between junctions J5-7 and 23-27 of the M25 were the first to be designed to the all lane running standard, and were completed in 2014. The performance of both schemes was monitored and reports published after one, two and three years of operation which included an assessment of safety and performance data.</p><p> </p><p>M25 3 year evaluation reports:</p><p> </p><p>https://www.gov.uk/government/publications/m25-junction-5-to-7-third-year-evaluation-report</p><p> </p><p>https://www.gov.uk/government/publications/m25-junction-23-to-27-third-year-evaluation-report</p><p> </p><p>The review shows that the all lane running sections are performing well and in line with expectations; successfully increasing capacity and improving journeys for motorists. These reviews found that the M25 schemes delivered an overall 27% safety improvement.</p><p> </p> answering member constituency Hereford and South Herefordshire
	creator	1528
	publisher	25259
	tabling member	1528

1128296

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	22/05/2019
	date tabled	22/05/2019
	ddp created	24/05/2019 08:59:06
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:19:33 10/06/2019 14:00:12
	hansard heading	Cannabis: Medical Treatments
	house id	1
	identifier	257472
	legislature	25259
	parliament number	57
	question first answered	10/06/2019 13:28:33
	question text	To ask the Secretary of State for Health and Social Care, which countries his Department is engaging with in order to learn from their experiences in getting patients access to medical cannabis.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257472
	type	WrittenParliamentaryQuestion
	uin	257472
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528

1128297

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	22/05/2019
	date tabled	22/05/2019
	ddp created	24/05/2019 08:59:08
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:19:36 10/06/2019 14:00:11
	hansard heading	Cannabis: Medical Treatments
	house id	1
	identifier	257473
	legislature	25259
	parliament number	57
	question first answered	10/06/2019 13:28:33
	question text	To ask the Secretary of State for Health and Social Care, what evidence his Department has reviewed from other countries on the effectiveness of cannabis as a medicine.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257473
	type	WrittenParliamentaryQuestion
	uin	257473
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In developing its policy on cannabis-based products for medicinal use, the Government looked at approaches taken by other countries to learn from their experience. Broadly two approaches have been taken: to regulate as a medicine (both licenced and unlicensed) as in the United Kingdom or to regulate outside of the medicinal regime as in Canada. In reviewing the available international evidence, the Chief Medical Officer for England and Chief Medical Adviser to the UK Government, looked at evidence reviews from the United States, Ireland, Australia, and the World Health Organization. Departmental officials have also reviewed information from a wide range of other countries and have spoken to the authorities and organisations in Australia, Canada, Denmark, the Netherlands, and the United States (New York).</p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528

1128298

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	22/05/2019
	date tabled	22/05/2019
	ddp created	24/05/2019 08:59:10
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:19:38 07/06/2019 15:23:01
	hansard heading	NHS: Training
	house id	1
	identifier	257474
	legislature	25259
	parliament number	57
	question first answered	07/06/2019 14:51:23
	question text	To ask the Secretary of State for Health and Social Care, which groups of NHS staff will receive training from Health Education England.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257474
	type	WrittenParliamentaryQuestion
	uin	257474
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>Health Education England has been commissioned to produce e-learning resources for clinicians and healthcare professionals to raise awareness of the regulation, guidance and evidence around cannabis-based products for medicinal use, and to build confidence in appropriate use and prescribing of such products. These resources will shortly be available and will be accessible by all healthcare professionals across the United Kingdom.</p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528

1128299

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	22/05/2019
	date tabled	22/05/2019
	ddp created	24/05/2019 08:59:13
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:19:40 10/06/2019 13:57:04
	hansard heading	Cannabis: Medical Treatments
	house id	1
	identifier	257475
	legislature	25259
	parliament number	57
	question first answered	10/06/2019 13:26:43
	question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care on 20 May 2019, Official Report, column, 571, what plans he has to include observational trials in building up the existing evidence-base.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257475
	type	WrittenParliamentaryQuestion
	uin	257475
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>In all areas of scientific research, a range of evidence builds our understanding. This includes individual cases and observational trials. It is the promise shown from these observational studies and experience, from all around the world, that provides the basis for public funding of further research into the use of cannabis based products as medicines through the National Institute for Health Research. This further clinical research will provide a greater level of understanding of cannabis-based medicines, how to use them to best effect, who may benefit and under what circumstances, how cannabis interacts with other medications and define further any contraindications. It is this level of research outcomes that will provide confidence to prescribers and the information necessary to make routine funding decisions within the National Health Service.</p><p>The existing experience, studies and research in this area will be used by the National Institute for Health and Care Excellence to develop their clinical guidelines due to be published later this year.</p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528

1128300

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	22/05/2019
	date tabled	22/05/2019
	ddp created	24/05/2019 08:59:16
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:19:44 10/06/2019 13:50:03
	hansard heading	Cannabis: Medical Treatments
	house id	1
	identifier	257476
	legislature	25259
	parliament number	57
	question first answered	10/06/2019 13:18:03
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost-effectiveness of patients receiving an NHS prescription for wholeplant medical cannabis.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257476
	type	WrittenParliamentaryQuestion
	uin	257476
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528

1128441

	human indexable
	published
	registered interest
	answer date	04/06/2019
	date	23/05/2019
	date tabled	23/05/2019
	ddp created	24/05/2019 09:05:12
	answering body	Department of Health and Social Care
	question status	Tabled
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	ddp modified	24/05/2019 09:25:41 10/06/2019 13:55:04
	hansard heading	Cannabis: Medical Treatments
	house id	1
	identifier	257705
	legislature	25259
	parliament number	57
	question first answered	10/06/2019 13:23:02
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of evidence base on the cost-effectiveness of medical cannabis.
	session	2017/19
	session number	1
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	title	House of Commons Tabled Parliamentary Question 2017/19 257705
	type	WrittenParliamentaryQuestion
	uin	257705
	version	1
	written parliamentary question type	Ordinary
	answer	answer answer text <p>An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</p><p><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></p><p>This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</p><p>In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></p> answering member constituency South Ribble
	creator	1528
	publisher	25259
	tabling member	1528